Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Search by Keyword
Sort By
  • Hepatitis C SIG: HCV Treatment in Persons Who Inject Drugs

    Product not yet rated Contains 9 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations. This program is targeting HCV SIG clinicians, public and global health experts as well as patient advocates with the goal of sharing expertise on how to improve the cascade of care in the “difficult to reach” populations.  

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.



    Camilla S. Graham

    John W. Ward

    Alain H. Litwin

    Christian B. Ramers

    Diana Sylvestre

    Natasha Martin

    Lynn E. Taylor

  • NAFLD SIG: Non-Invasive Diagnosis of NASH: We're getting There

    Product not yet rated Contains 6 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Review the rapidly evolving landscape of non-invasive diagnostic tools for the diagnosis and staging of NAFLD. Non-invasive Diagnosis of NASH will look at the current role of — and available alternatives to —liver biopsy in the assessment of NASH and discuss the controversial issue of utilizing liver biopsy as the “gold-standard” endpoint in clinical trials. The program will review the application of biomarkers in assessing dynamic changes in NAFLD as it pertains to response to therapies and the potential that such biomarkers (serum or imaging) could predict clinical outcomes in NAFLD.

    Zachary D. Goodman

    Anna Mae Diehl

    Quentin M. Anstee

    Stephen A. Harrison

    Christopher Leptak

    Mary E. McCarthy Rinella

  • Alcoholic Liver Disease SIG: Alcoholic Hepatitis: New Therapeutic Strategies Beyond Prednisolone

    Contains 5 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Alcoholic Hepatitis is the most severe form of Alcoholic Liver Disease (ALD). Currently the most effective form of treatment is Prednisolone, to which many patients do not respond. In the last years, there has been great interest in the development of new targeted therapies for alcoholic hepatitis. In the U.S., there are 4 NIAAA-funded consortia to develop such therapies. In this symposium, we seek to address this issue through the review of current pharmacological therapies, ongoing NIAAA-funded studies, and evaluation of the management of alcohol use disorders in advanced ALD patients. 

    Gene Y. Im

    Vijay Shah

    Shiv K. Sarin

    Craig J. McClain

    Ramon Bataller

  • Pediatric Liver Disease SIG: Drug Induced Liver Injury in Children: Causes, Criteria, and Complications

    Product not yet rated Contains 2 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    As the number and type of drugs used to treat pediatric illnesses proliferate, and the push to make new drugs available for children gains speed, understanding how to recognize drug-induced liver injury is increasingly important for pediatric liver providers. This program will focus on challenges and opportunities associated with the diagnosis and management of DILI that are unique to the pediatric population. Clinical presentations include surreptitious elevation of serum aminotransferase levels, acute liver injury with or without acute liver failure, and chronic liver disease.

    Binita M. Kamath

    Maclovio J. Lopez

  • Chronic Hepatitis B and Pregnancy: Management and Prevention of Vertical Transmission

    Contains 1 Component(s) Recorded On: 09/14/2017

    Webinar hosted by the Hepatitis B Special Interest group on September 14, 2017.

    The management of women of child-bearing age and pregnant women with chronic hepatitis B requires special consideration due to the potential effects of antiviral therapy on unborn fetus and potential for hepatitis flares for pregnant and postpartum women. While universal maternal screening programs and immunoprophylaxis to newborns have greatly reduced mother-to-child-transmission (MTCT), immunoprophylaxis can fail in up to 30% of infants, especially in mothers with high HBV DNA levels and positive HBeAg. As a result, there has been growing support for the initiation of antiviral therapy during late pregnancy in highly viremic women, and this has been shown in a recent randomized controlled trial to be safe and effective in preventing MTCT with antiviral therapy starting at 30-week gestation and in combination with birth-dose HBV immunoglobulin (HBIG) and vaccination followed by completion of the 3-dose vaccine series.  

    Mindie H. Nguyen (Moderator)

    Mindie H. Nguyen, MD, MAS, AGAF, FAASLD is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, School of Medicine, Stanford University in Palo Alto, California, USA. Her main fields of scientific and clinical interest are the epidemiology and management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver cancer, with over 100 peer- reviewed scientific journal articles. She has served as a member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group, HBV Special Interest Group, Education Committee and the Hepatology Associate Committee for the AASLD and as research mentor for over 100 trainees and faculty.

    Tram T. Tran

    Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Calvin Q. Pan

    Calvin Pan, MD is Clinical Professor of Medicine at the Division of Gasteroenterology and Hepatology in NYU Langone Medical Center in New York. Dr. Pan currently chairs the Online Learning Committee of AASLD. His research interest is a focus on the natural history of viral hepatitis, antiviral therapy and the prevention of vertical transmission of hepatitis virus. As the leading author, Dr. Pan has presented original articles in many high impact journals including the New England Journal of Medicine and Hepatology. He is the recipient of the Mastership Award from the American College of Physicians.

  • Surrogate Endpoints in Primary Sclerosing Cholangitis (PSC)

    Product not yet rated Contains 1 Component(s) Recorded On: 09/12/2017

    Webinar hosted by the Cholestatic and Biliary Diseases Special Interest group on September 12, 2017.

    This webinar, presented by the Cholestatic and Biliary Diseases SIG, will focus on the complex topic of Surrogate Endpoints in PSC. The webinar will discuss the Natural History of PSC and the resulting difficulty in identifying relevant endpoints for prognostication and for use in clinical trials. Promising candidate endpoints will be specifically addressed based on the latest clinical research. 

    David Assis (Moderator)

    Dr. David Assis is an assistant professor of medicine in the section of Digestive Diseases at Yale University School of Medicine. His research focuses on autoimmune liver diseases including autoimmune hepatitis and primary sclerosing cholangitis, using animal models and translational approaches including early drug development for autoimmune and cholestatic liver diseases. Dr. Assis is a steering committee member of the North American Consortium for Autoimmune Liver Diseases, and is also currently serving as secretary for the Cholestatic and Biliary Diseases SIG of the AASLD.

    Christopher L. Bowlus

    Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.

    Cyriel L. Ponsioen

    Dr. Cyriel Ponsioen works as senior staff member at the Department of Gastroenterology & Hepatology at the AMC. The focus of his clinical as well as research activities lies in inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The former mainly focuses on microbiota research in IBD. As for PSC, he has built up a research line in epidemiology, disease course, and biomarkers, and he leads a research line looking into the relationship between the gut and the biliary tree. Within the international PSC Study Group he is currently co-chair of the Working Group on Natural History and Biomarkers.

    John E. Eaton

    Dr. John Eaton is a transplant Hepatologist with a clinical and research focus on cholestatic liver diseases with an emphasis on primary sclerosing cholangitis (PSC) and related comorbid conditions. His clinical practice involves seeing a large volume of patients with PSC and PSC complicated by cholangiocarcinoma. Dr. Eaton’s research focus is the conduction of clinical trials and the discovery of novel biomarkers (including magnetic resonance imaging technologies) that can predict disease outcomes.

  • Fibrosis Regression: Mechanisms and Clinical Consequences

    Product not yet rated Contains 1 Component(s) Recorded On: 09/11/2017

    Webinar hosted by the Liver Fibrosis Special Interest group on September 11, 2017.

    For most of the modern era in medicine, cirrhosis has been regarded as an irreversible condition. For most of the modern era in medicine, cirrhosis has been regarded as an irreversible condition.  Contrary to this perception, cirrhosis in animal models of liver injury has long been known to be reversible and case reports from decades ago documenting “reversal” of cirrhosis indicated that fibrosis regression was also possible in human liver disease. The availability of effective therapies for liver diseases such as chronic viral hepatitis has made it possible to determine the effects of fibrosis regression on clinical outcomes. This webinar will explore the fundamental cellular mechanisms of fibrosis regression, evaluate the evidence for fibrosis regression in patients who have undergone successful antiviral treatment and examine the impact of fibrosis regression on clinical outcomes.

    Kyle Brown (Moderator)

    Dr. Kyle Brown is an Associate Professor of Medicine at the University of Iowa.  She completed her gastroenterology and hepatology training at the University of Virginia in Charlottesville.  After serving as GI-Hepatology Program Director at Iowa for over a decade, she continues to be involved in medical student, resident and fellow education.  Her clinical practice at the University and at the Iowa City Veterans Administration Hospital focuses on general hepatology.  Her research interests include complications of advanced liver disease with a specific focus on alterations in iron metabolism.

    Prakash Raman

    Dr Ramachandran is an MRC Clinician Scientist at the University of Edinburgh and an Honorary Consultant Hepatologist at the Royal Infirmary of Edinburgh. His research interest is in the basic mechanisms of liver fibrosis, in particular the role of the immune system in regulating fibrogenesis and fibrosis regression.

    During his PhD, working with Professor John Iredale and Professor Stuart Forbes, Dr Ramachandran identified and characterised a novel macrophage population which orchestrated the resolution of liver fibrosis. He has recently been awarded an MRC Fellowship to further define hepatic macrophage functional heterogeneity in both pre-clinical models and human chronic liver disease.

    Andres Duarte-Rojo

    Dr. Andrés Duarte-Rojo is a clinical investigator at the level of Associate Professor at the University of Arkansas for Medical Sciences (UAMS) in Little Rock. He completed his gastroenterology fellowship at the Instituto Nacional de Ciencias Médicas y Nutrición, in México City, followed by hepatology fellowships at the University of Toronto and Mayo Clinic in Rochester, MN. His academic training includes a Master and a Doctorate in Medical Science from the University of México. His main research interests include clinimetrics in cirrhosis with a focus in noninvasive markers of fibrosis, exercise in end stage liver disease, and clinical outcomes in liver transplantation.

  • New DAA's and Controversies in HCV: What Clinicians Need to Know

    Contains 1 Component(s) Recorded On: 09/07/2017

    Webinar hosted by the Hepatitis C Special Interest group on September 7, 2017.

    Two new HCV meds have been approved over the summer. This webinar is meant to provide an update on how these fit into current practice. We will also cover the ongoing controversy on the risk of HCC with DAA's and the recent Cochrane report on the benefits of HCV therapy. 

    Paul Y. Kwo (Moderator)

    Dr. Kwo is currently Professor of Medicine and  Director of Hepatology at the Stanford University where he joined the faculty  in November 2016. Prior to joining the faculty at Stanford, he was  at Indiana University for   21 years where he served as the Medical Director of Liver Transplantation.  He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C.  He has won multiple awards, both at the university, local, and national level.

    Andrew J. Muir (Moderator)

    Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

    George Ioannou

    Dr. Ioannou is an Associate Professor of Medicine at the University of Washington and the Director of Hepatology at the Veterans Affairs Puget Sound Healthcare System. He is also the co-Director of the Hepatitis C Innovation Team for the Veterans Affairs VISN 20. His research interests include understanding the response to antiviral treatment for hepatitis C and the long-term implications of antiviral treatment in large, real-world cohorts of patients.

    Robert S. Brown, Jr

    Dr. Brown is the Vice Chair of Transitions of Care and Clinical Chief of the Division of Gastroenterology and Hepatology, as well as a Gladys and Roland Harriman Professor of Medicine, at Weill Cornell Medical College in New York City. His research focuses on the clinical and cost outcomes of liver disease, in particular, viral hepatitis and liver transplantation, using randomized clinical trials, multivariate linear and logistic regression, survival analysis, and decision tree and cost-effectiveness analyses. Several of his liver transplantation studies were funded by the National Institute of Diabetes and Digestive and Kidney Diseases, as well as the pharmaceutical industry, including several multicenter studies to investigate antiviral prophylaxis strategies and various immunosuppressive agents following liver transplantation. Dr. Brown received the Young Investigator Award from the American Society of Transplant Physicians early in his career, in 1996. In 2009, he was honored with the Senior Attending Teaching Award.

    Doris B. Strader

  • Frailty the “Sixth Vital Sign” in Cirrhosis - How Do We Diagnose It and What Can We Do When We Find It?

    Product not yet rated Contains 1 Component(s) Recorded On: 08/31/2017

    Webinar hosted by the Acute on Chronic Liver Failure Special Interest group on August 31, 2017.

    Frailty is a critical determinant of outcomes in patients with cirrhosis. In this webinar we will present practical methods to assess and quantify frailty in both the outpatient and inpatient clinical settings. We will also provide recommendations on specific interventions once frailty is identified.

    Jody Olson (Moderator)

    Dr. Jody Olson is currently an Assistant Professor in the departments of Internal Medicine and Surgery at the University of Kansas Medical Center and is primarily affiliated with the liver transplant program.  His clinical interests are centered on caring for patients with advanced liver disease in the inpatient and intensive care setting.  His research is focused on the critically ill liver disease patient, both acute and chronic and works in the area of acute-on-chronic liver failure.  In addition, he is the site primary investigator for the NIH sponsored United States Acute Liver Failure Study Group at the University of Kansas.

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

  • 2017 Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease

    Product not yet rated Contains 35 Component(s) Recorded On: 03/19/2017

    This course spearheads a development strategy to disseminate new knowledge and treatment options in NAFLD.

    The 2017 Emerging Trends Conference will spearhead a development strategy to disseminate new knowledge and treatment options in NAFLD. Major advances in the epidemiology, natural history, pathogenesis and diagnostic modalities have been uncovered although no established treatment has been approved. By facilitating new and exciting translational and therapeutic research in NAFLD, collaborations among clinicians, industry, academic institutions, and public health agencies will be well equipped to deal with this epidemic that threatens our quality of life.

    Zobair M. Younossi

    Keith D. Lindor

    Mary E. McCarthy Rinella

    Elisabetta Bugianesi